Williams DS, Mouradov D, Browne C, et al. - Researchers investigated the predictive utility of TP53 overexpression for 5-year disease-free survival in a cohort of 264 patients with stage III colorectal cancer, grouped by adjuvant treatment. In an independent retrospective cohort of 274 patients with stage III disease, researchers validated the findings. The prospective and retrospective cohorts had 53% and 52% of participants, respectively, who displayed overexpression of TP53 protein (TP53+). As per combined cohort-stratified analysis adjusted for clinicopathological variables and DNA mismatch repair status, there was a significant interaction between TP53 expression and adjuvant treatment for disease-free survival. Findings suggested that only participants with low-level TP53 protein expression benefit from adjuvant chemotherapy in stage III colorectal cancer. Identification of TP53+ tumors may assist in identifying patients that may benefit from more aggressive treatment or follow-up.